Related Experiment Video

Updated: Sep 20, 2026

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

Cilengitide Merck

Jeffrey W Smith1

  • 1Burnham Institute, 10901 N Torrey Pines Road, La Jolla, CA 92037-1005, USA. jsmith@burnham.org

Current Opinion in Investigational Drugs (London, England : 2000)
|August 7, 2003
PubMed

Insights

Cilengitide, an integrin antagonist, is being investigated for various cancers. Clinical trials are evaluating its efficacy in non-small-cell lung cancer, pancreatic cancer, and glioblastoma.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Merck KGaA is developing cilengitide, a novel integrin antagonist.
  • Cilengitide exhibits anti-angiogenic properties, targeting tumor blood vessel formation.

Purpose of the Study:

  • To evaluate cilengitide's potential in treating various cancer types.
  • To assess cilengitide's efficacy as a monotherapy and in combination with other agents.

Main Methods:

  • Phase II clinical trials initiated in 1999 for non-small-cell lung cancer (monotherapy) and pancreatic cancer (combination with gemcitabine).
  • Phase I and Phase I/II trials in glioblastoma were underway by February 2002.

Main Results:

  • Clinical trials were ongoing as of February 2002, indicating continued investigation.
  • Specific efficacy results are not detailed in the provided abstract.

Conclusions:

  • Cilengitide is under active clinical investigation for multiple cancer indications.
  • The development of cilengitide represents a targeted approach to cancer therapy through integrin antagonism.

More Related Videos

Modification and Functionalization of the Guanidine Group by Tailor-made Precursors09:45

Modification and Functionalization of the Guanidine Group by Tailor-made Precursors

Published on: April 27, 2017

Related Concept Videos

Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...